Cibinetide • Helix B Surface Peptide • EPO-Derived Repair Signal
ARA-290 is an 11 amino acid peptide derived from the tissue protective domain of erythropoietin. It is researched for small fiber neuropathy, nerve regeneration, inflammation control, metabolic improvement, and tissue protection without increasing red blood cell production, hematocrit, blood viscosity, or blood pressure.
ARA-290 is a synthetic 11 amino acid peptide derived from the tissue protective domain of erythropoietin (EPO). Its sequence is Pyr-Glu-Glu-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. It is also known as cibinetide and helix B surface peptide (HBSP). Its molecular weight is 1257 Da.
If you have heard of EPO, you know it as the hormone your kidneys produce to stimulate red blood cell production. Athletes have abused it for decades to increase oxygen carrying capacity. But EPO also has powerful tissue protective and anti-inflammatory effects that are completely separate from its blood building activity.
ARA-290 has been studied in multiple Phase 2 clinical trials across sarcoidosis-associated small fiber neuropathy and diabetic neuropathy, giving it a more substantial human evidence base than many experimental repair peptides.
ARA-290 activates the tissue-protective EPOR/CD131 receptor complex found in stressed or injured tissue. This pathway coordinates repair and inflammation control without activating the receptor responsible for red blood cell production. Receptor research.
IRR activation can reduce inflammatory signaling and immune overactivation. Animal studies found changes in T-cell responses and reduced spinal microglial activation, supporting research into inflammatory neuropathies. Human benefits across autoimmune conditions remain unproven. Immune study · Neuropathy study.
Preclinical injury models report less programmed cell death, oxidative stress, inflammation, and tissue damage after ARA-290 treatment. These findings support its tissue-protection rationale but are not established organ-protection benefits in people. Oxidative-stress study · Kidney study.
In a small randomized sarcoidosis trial, 28 days of ARA-290 was associated with improved neuropathy symptoms and greater corneal nerve-fiber density. A diabetes study found a similar signal in participants with low baseline nerve density. Sarcoidosis trial · Diabetes trial.
ARA-290 retains EPO’s tissue-protective signaling without activating its classic erythropoietic pathway. It therefore avoids the red-cell-building response and related increases in hematocrit and blood viscosity seen with EPO. EPOR/CD131 research.
The benefits of ARA-290 are supported by multiple human clinical trials, which puts it ahead of many peptides in the healing and recovery category where evidence is often limited to animal models.
The strongest clinical evidence comes from neuropathy studies. In sarcoidosis patients, ARA-290 produced a 28% reduction in Small Fiber Neuropathy Screening List scores compared to 9% for placebo.
Corneal confocal microscopy confirmed increased nerve fiber area and density after 28 days. GAP-43 positive regenerating nerve fibers increased significantly in the 4mg dose group.
In type 2 diabetic patients, ARA-290 improved HbA1c by 0.21%, improved cholesterol to HDL ratio, increased HDL, and decreased triglycerides.
ARA-290 improved pain and physical functioning dimensions of quality of life assessments. The 6 minute walk test improved by 18.7 meters versus a 15.1 meter decline in placebo.
ARA-290 reduces pro-inflammatory cytokines including TNF-alpha, IL-1 beta, and IL-6 through NF-kB inhibition without broad immunosuppression.
Preclinical research shows protection in kidney ischemia reperfusion injury, age-related cardiac inflammation, pancreatic islet transplantation, and ischemic stroke models.
A 2021 study showed cibinetide inhibited osteoclastogenesis and increased cortical and trabecular bone mineral density after one month in mice.
Unlike treatments that only mask neuropathic pain, ARA-290 has demonstrated symptom relief plus measurable nerve-fiber regeneration in controlled human trials.
Sign in or create a free account to view this content.
Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.
Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.
Swirl or roll the vial until the contents dissolve; do not shake.
Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.
The strongest stacking rationale is not overlap. It is tissue targeting. ARA-290 is most interesting for nerve injury and neuroinflammation, while BPC-157, TB-500, KPV, and Cartalax are generally aimed at different parts of the repair and inflammation cascade.
No published data exists on this combination. ARA-290 works through the innate repair receptor, BPC-157 primarily through VEGFR2 upregulation and angiogenesis, and TB-500 through actin upregulation and cell migration.
Theoretical but logical. KPV supports inflammatory control while ARA-290 supports nerve repair and tissue-protective signaling. No published studies have tested the combination.
More speculative. Cartalax is generally discussed around cartilage and connective tissue bioregulation, while ARA-290 is more focused on nerve repair and inflammation. No combination data exists.
ARA-290 has demonstrated a favorable safety profile across published clinical trials. Reported adverse events were generally mild and occurred at rates similar to placebo.
We consider ARA-290 a specialist peptide that delivers when standard options fall short. It excels at reducing nerve pain, calming chronic inflammation, and supporting microvascular repair. Users dealing with neuropathy, long COVID, or persistent inflammatory conditions often report meaningful relief.
It’s not a daily foundational peptide for everyone, but in the right context it becomes a standout. We recommend targeted cycles rather than indefinite use. Strong niche tool with real-world utility for those who need it.
Peptide Protocols
Send us a message and we’ll reply to the email address you provide.